Skip to main content
logo
Pyxis Oncology, Inc. (PYXS)
NASDAQ: PYXS · Real-Time Price · USD
3.230
-0.090 (-2.71%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Pyxis Oncology Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
11.0413.8616.15---
Revenue Growth
291.42%-14.17%----
Cost of Revenue
2.392.390.48---
Gross Profit
8.6511.4715.67---
Selling, General & Admin
22.819.6222.4930.8337.3518.66
Research & Development
75.5673.758.7549.5986.1351.05
Operating Expenses
98.3693.3281.2480.42123.4869.72
Operating Income
-89.71-81.85-65.57-80.42-123.48-69.72
Interest & Investment Income
2.093.617.046.632.760.02
Earnings From Equity Investments
------0.23
Other Non Operating Income (Expenses)
------6.05
EBT Excluding Unusual Items
-87.62-78.24-58.53-73.79-120.72-75.98
Pretax Income
-87.62-78.24-79.5-73.79-120.72-75.98
Income Tax Expense
1.11.39-2.16---
Net Income
-88.73-79.62-77.33-73.79-120.72-75.98
Net Income to Common
-88.73-79.62-77.33-73.79-120.72-75.98
Net Income Growth
------
Shares Outstanding (Basic)
63625840338
Shares Outstanding (Diluted)
63625840338
Shares Change
3.27%6.33%46.46%20.80%288.93%724.14%
EPS (Basic)
-1.40-1.28-1.32-1.85-3.65-8.95
EPS (Diluted)
-1.40-1.28-1.32-1.85-3.65-8.95
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-67.92-63.51-57.91-77.44-95.73-35.87
Free Cash Flow Per Share
-1.07-1.02-0.99-1.94-2.90-4.22
Gross Margin
78.37%82.77%97.06%---
Operating Margin
-812.74%-590.60%-406.11%---
Profit Margin
-803.83%-574.55%-478.95%---
Free Cash Flow Margin
-615.32%-458.30%-358.66%---
EBITDA
-85.53-77.33-62.59-78.49-122.77-69.07
D&A For EBITDA
4.184.512.981.930.710.65
EBIT
-89.71-81.85-65.57-80.42-123.48-69.72
Revenue as Reported
13.8613.8616.15---
SEC Filings: 10-K · 10-Q